SAVA benefits from greater awareness. Maybe due to financing. But I prefer Missling's tight financia mgt to getting diluted into the ground. The awareness will change after approval. dont overestimate wall streets knowledge, many of their funds only want to invest in profitable biotechs with larger market caps. So they simply ignore a company like this. I have spoken with Wall street types andthey barely know this company.